MedTrace Logo

A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

NCT06525935 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 469

Last updated 2026-04-17

No results posted yet for this study

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidity.

Conditions

Interventions

DRUG

Placebo

Placebo will be volume- matched and administered subcutaneously (SC) once weekly.

DRUG

Enicepatide

Enicepatide will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Carmot Therapeutics, Inc., a Member of the Roche Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-16
Primary Completion
2025-12-08
Completion
2025-12-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06525935 on ClinicalTrials.gov